Marker Therapeutics Inc Quick Ratio (MRKR) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Marker Therapeutics inc   (NASDAQ: MRKR)

Marker Therapeutics Inc 's Quick Ratio

MRKR's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Marker Therapeutics Inc 's Cash & cash equivalent grew by 47.71 % in the Q2 2026 sequentially, while Current Liabilities decreased, this led to improvement in Marker Therapeutics Inc 's Quick Ratio to 9.1, above Marker Therapeutics inc average Quick Ratio.

Within Major Pharmaceutical Preparations industry 116 other companies have achieved higher Quick Ratio than Marker Therapeutics Inc in second quarter 2026. While Quick Ratio total ranking has improved so far during the Q2 2026 to 507, from total ranking in the first quarter 2026 at 671.

Explain Quick Ratio?
How much Cash & cash equivalents MRKR´s has?
What are MRKR´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

MRKR Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change -43.42 % 45.44 % -34.36 % -3.32 % 116.89 %
Y / Y Cash & cash equivalent Change 110.58 % 8.93 % -16.28 % 95.45 % 34.12 %
Quick Ratio MRQ 9.1 4.1 7.07 5.26 2.45
MRKR's Total Ranking # 507 # 671 # 452 # 0 # 842
Seq. Current Liabilities Change -33.48 % 59.97 % -32.03 % -21.78 % 71 %
Seq. Cash & cash equivalent Change 47.71 % -7.17 % -8.65 % 68.13 % -23.6 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 117
Healthcare Sector # 179
Overall Market # 507


Quick Ratio Statistics
High Average Low
24.55 4.55 0
(Dec 31 2019)   (Mar 31 2013)




Financial Statements
Marker Therapeutics Inc 's Current Liabilities $ 2 Millions Visit MRKR's Balance sheet
Marker Therapeutics Inc 's Cash & cash equivalent $ 22 Millions Visit MRKR's Balance sheet
Source of MRKR's Sales Visit MRKR's Sales by Geography


Cumulative Marker Therapeutics Inc 's Quick Ratio

MRKR's Quick Ratio for the trailling 12 Months

MRKR Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth -14.78 % 18.75 % 10.69 % 25.69 % 35.28 %
Y / Y Cash & cash equivalent TTM Growth 34.88 % 18.82 % 22.19 % 40.95 % 1.23 %
Quick Ratio TTM 6.05 4.36 4.66 4.48 3.82
Total Ranking TTM # 3495 # 2690 # 2799 # 0 # 2896
Seq. Current Liabilities TTM Growth -13.72 % 9.17 % -8.76 % -0.84 % 20.22 %
Seq. Cash & cash equivalent TTM Growth 19.6 % 2.11 % -5.13 % 16.41 % 5.36 %

Quick ratio ranking by company, industry and sector >> Back to MRKR Financial Strength Comparisons >> Go to Compare MRKR Quick Ratio to its Competitors

On the trailing twelve months basis MRKR Cash & cash equivalent more than doubled by 110.58 % in Q2 2026 year on year, while Current Liabilities plummeted to $2 millions, this led to increase in in Marker Therapeutics Inc 's Quick Ratio to 6.05, above MRKR average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 419 other companies have achieved higher Quick Ratio than Marker Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 2690 to 3495.

Explain Quick Ratio?
How much Cash & cash equivalents MRKR´s has?
What are MRKR´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 420
Healthcare Sector # 855
Within the Market # 3495


trailing twelve months Quick Ratio Statistics
High Average Low
18.24 4.08 0
(Sep 30 2019)   (Sep 30 2013)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Boundless Bio Inc   25.00 $ 194.230  Millions$ 7.768  Millions
Sionna Therapeutics Inc   24.88 $ 268.300  Millions$ 10.782  Millions
Prothena Corporation Public Limited Company  24.72 $ 288.193  Millions$ 11.658  Millions
Zenas Biopharma Inc   24.28 $ 1,597.761  Millions$ 65.818  Millions
Neuphoria Therapeutics Inc   23.89 $ 19.866  Millions$ 0.832  Millions
Innoviva Inc   23.77 $ 1,118.871  Millions$ 47.064  Millions
Pepgen Inc   23.51 $ 211.674  Millions$ 9.005  Millions
Kailera Therapeutics Inc   23.41 $ 1,958.240  Millions$ 83.651  Millions
Equillium Inc   23.07 $ 57.164  Millions$ 2.478  Millions
Relmada Therapeutics Inc  21.72 $ 217.731  Millions$ 10.023  Millions
Keros Therapeutics Inc   21.20 $ 257.606  Millions$ 12.153  Millions
Protagonist Therapeutics inc   21.05 $ 782.576  Millions$ 37.181  Millions
Stablecoin Development Corporation  20.76 $ 7.122  Millions$ 0.343  Millions
Rhythm Pharmaceuticals Inc   20.65 $ 596.183  Millions$ 28.868  Millions
Structure Therapeutics Inc   20.31 $ 1,342.700  Millions$ 66.113  Millions
Scynexis Inc   19.69 $ 114.696  Millions$ 5.825  Millions
Q32 Bio Inc   19.68 $ 106.270  Millions$ 5.401  Millions
Damora Therapeutics Inc   19.62 $ 540.515  Millions$ 27.550  Millions
Kairos Pharma Ltd   19.12 $ 5.067  Millions$ 0.265  Millions
Minerva Neurosciences Inc   19.02 $ 75.267  Millions$ 3.958  Millions
Abcellera Biologics Inc   18.05 $ 960.143  Millions$ 53.189  Millions
Sellas Life Sciences Group Inc   17.29 $ 138.443  Millions$ 8.006  Millions
Whitehawk Therapeutics Inc   17.17 $ 190.000  Millions$ 11.069  Millions
Forte Biosciences Inc   17.12 $ 347.331  Millions$ 20.289  Millions
Ovid Therapeutics Inc   17.01 $ 169.769  Millions$ 9.980  Millions
Bioage Labs Inc   16.59 $ 318.745  Millions$ 19.217  Millions
Olema Pharmaceuticals Inc   16.48 $ 873.571  Millions$ 53.014  Millions
Erasca Inc   16.41 $ 610.496  Millions$ 37.200  Millions
Janux Therapeutics Inc   16.14 $ 970.913  Millions$ 60.152  Millions
Edgewise Therapeutics inc   15.86 $ 460.709  Millions$ 29.042  Millions

Date modified: 2026-09-12T06:13:23+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.